Alto Neuroscience ANRO ALTO-100 — Direct external program expenses:

Other product segments

Similar metrics at other companies

IDYAIDE034 — External Clinical Development Expenses

$6.81M+17,816%

WVEAATD Program — Research And Development Expense

$1.75M+21.0%

IDYAIDE161 — External Clinical Development Expenses

$1.61M-34.4%

IDYAIDE397 — External Clinical Development Expenses

$3.52M-6.0%

STOKOther External Program Costs — Operating Expenses

-$3.18M-73.8%

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

Questions, answered.

What is Alto Neuroscience's ALTO-100 — direct external program expenses:?

Alto Neuroscience (ANRO) reported ALTO-100 — direct external program expenses: of $1.76M in Q1 2026.

How has Alto Neuroscience's ALTO-100 — direct external program expenses: changed year-over-year?

Alto Neuroscience's ALTO-100 — direct external program expenses: increased by 56.9% year-over-year, from $1.12M to $1.76M.

What is the long-term trend for Alto Neuroscience's ALTO-100 — direct external program expenses:?

Over 2 years (2023 to 2025), Alto Neuroscience's ALTO-100 — direct external program expenses: has grown at a -13.0% compound annual growth rate (CAGR), from $7.75M to $5.87M.

What does ALTO-100 — direct external program expenses: mean?

This metric represents the direct research and development costs specifically attributable to the ALTO-100 clinical program, including expenses for clinical trials, manufacturing, and external research services. It serves as a key indicator of the capital intensity and development progress of this specific therapeutic asset. Monitoring these costs helps investors assess the resource allocation efficiency and the financial commitment required to advance the program through its clinical milestones.